Search

Your search keyword '"Yang, Shyh-Ming"' showing total 232 results

Search Constraints

Start Over You searched for: Author "Yang, Shyh-Ming" Remove constraint Author: "Yang, Shyh-Ming"
232 results on '"Yang, Shyh-Ming"'

Search Results

3. Supplementary Figure S1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

4. Data from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

5. Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

6. Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

7. Supplementary Table 1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

8. Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

9. Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

10. Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

11. RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

13. Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

14. Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

15. Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

16. Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

17. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma

21. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.

22. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia

25. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome

28. Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties

29. Abstract 1745: Application of BET/CBP/p300 multi-bromodomain inhibitors as a novel therapeutic strategy for MLL-rearranged acute lymphoblastic leukemia

32. Coupling reactions and coupling-alkylations of thiophenecarbaldehydes promoted by samarium diiodide

34. Indolecarbonyl coupling reactions promoted by samarium diiodide: application to the synthesis of indole-fused compounds

38. Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol

39. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

40. Author response: Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol

41. Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol

42. Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity

44. Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)

48. A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models

50. A High-Throughput Screen Identifies 2,9-Diazaspiro[5.5]Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models

Catalog

Books, media, physical & digital resources